c-Myc and Sp1 Contribute to Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency Virus Type 1 Promoter
暂无分享,去创建一个
[1] J. Leonard,et al. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity , 1989, Journal of virology.
[2] G. Inghirami,et al. Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells. , 1990, Science.
[3] J. Leonard,et al. Variable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes , 1991, Journal of virology.
[4] D. Margolis,et al. Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. , 1992, Virology.
[5] R. Pomerantz,et al. Sodium butyrate stimulation of HIV-1 gene expression: a novel mechanism of induction independent of NF-kappa B. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[6] C. Van Lint,et al. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. , 1996, Gene expression.
[7] E. Verdin,et al. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. , 1997, Genes & development.
[8] F. Kashanchi,et al. Rapid and sensitive detection of cell‐associated HIV‐1 in latently infected cell lines and in patient cells using sodium‐n‐butyrate induction and RT‐PCR , 1997, Journal of medical virology.
[9] A. Fornace,et al. Myc represses the growth arrest gene gadd45 , 1997, Oncogene.
[10] Q. Zhan,et al. Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents , 1998, Oncogene.
[11] Kou-Juey Wu,et al. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. , 1999, Science.
[12] K. Zeller,et al. Function of the c-Myc oncogenic transcription factor. , 1999, Experimental cell research.
[13] S. Salghetti,et al. Destruction of Myc by ubiquitin‐mediated proteolysis: cancer‐associated and transforming mutations stabilize Myc , 1999, The EMBO journal.
[14] C. Van Lint. Role of chromatin in HIV-1 transcriptional regulation. , 2000, Advances in pharmacology.
[15] J. Massagué,et al. Repression of p15INK4b expression by Myc through association with Miz-1 , 2001, Nature Cell Biology.
[16] T. Taira,et al. RECRUITMENT OF A TRANSCRIPTIONAL COREPRESSOR COMPLEX TO c-Myc BY MM-1, A c-Myc-BINDING PROTEIN* , 2001 .
[17] Yudong D. He,et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer , 2001, Nature Biotechnology.
[18] L. Penn,et al. Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor. , 2001, Journal of cell science.
[19] Anne F. Buckley,et al. Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc–dependent pathway , 2001, Nature Immunology.
[20] A. Gartel,et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[21] L. Penn,et al. Mechanism for the transcriptional repression by c-Myc on PDGF (β)-receptor , 2001 .
[22] F. Kashanchi,et al. Gene expression profile of HIV-1 Tat expressing cells: a close interplay between proliferative and differentiation signals , 2002, BMC Biochemistry.
[23] W. Löscher. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. , 2002, CNS drugs.
[24] C. Van Lint,et al. Diversity of acetylation targets and roles in transcriptional regulation: the human immunodeficiency virus type 1 promoter as a model system. , 2002, Biochemical pharmacology.
[25] D. Margolis,et al. Counterregulation of Chromatin Deacetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 (HIV-1) by the HIV-1 Repressor YY1 and HIV-1 Activator Tat , 2002, Molecular and Cellular Biology.
[26] Ben Berkhout,et al. Synergistic Activation of Human Immunodeficiency Virus Type 1 Promoter Activity by NF-κB and Inhibitors of Deacetylases: Potential Perspectives for the Development of Therapeutic Strategies , 2002, Journal of Virology.
[27] W. Löscher. Basic Pharmacology of Valproate , 2002 .
[28] D. Margolis,et al. Targeted Derepression of the Human Immunodeficiency Virus Type 1 Long Terminal Repeat by Pyrrole-Imidazole Polyamides , 2002, Journal of Virology.
[29] M. Giacca,et al. Regulation of HIV‐1 gene expression by histone acetylation and factor recruitment at the LTR promoter , 2003, The EMBO journal.
[30] Sharmistha Pal,et al. mSin3A/Histone Deacetylase 2- and PRMT5-Containing Brg1 Complex Is Involved in Transcriptional Repression of the Myc Target Gene cad , 2003, Molecular and Cellular Biology.
[31] M. Szyf,et al. Valproate Induces Replication-independent Active DNA Demethylation* , 2003, Journal of Biological Chemistry.
[32] R. Siliciano,et al. Resting CD4+ T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes , 2004, Journal of Virology.
[33] R. Siliciano,et al. The multifactorial nature of HIV-1 latency. , 2004, Trends in molecular medicine.
[34] R. Kuefer,et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer , 2004, British Journal of Cancer.
[35] L. Penn,et al. Repression of the human immunodeficiency virus type‐1 long terminal repeat by the c‐Myc oncoprotein , 2004, Journal of cellular biochemistry.
[36] R. Bosch,et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression , 2004, AIDS.
[37] R. Bosch,et al. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. , 2004, The Journal of infectious diseases.
[38] P. Atadja,et al. Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 , 2004, Clinical Cancer Research.
[39] P. Iversen,et al. In vivo Bioavailability and Pharmacokinetics of a c-MYC Antisense Phosphorodiamidate Morpholino Oligomer, AVI-4126, in Solid Tumors , 2005, Clinical Cancer Research.
[40] A. Marcello. Latency: the hidden HIV-1 challenge , 2006, Retrovirology.
[41] T. Kouzarides,et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor , 2005, The EMBO journal.
[42] Cheryl Jennings,et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study , 2005, The Lancet.
[43] Ernest Martinez,et al. Dual Regulation of c-Myc by p300 via Acetylation-Dependent Control of Myc Protein Turnover and Coactivation of Myc-Induced Transcription , 2005, Molecular and Cellular Biology.
[44] S. Voelter-Mahlknecht,et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. , 2005, International journal of molecular medicine.
[45] C. Lau,et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC , 2005, Molecular Cancer Therapeutics.
[46] D. Grayson,et al. Histone deacetylase inhibitors decrease reelin promoter methylation in vitro , 2005, Journal of neurochemistry.
[47] C. Van Lint,et al. COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells , 2005, Nucleic acids research.
[48] P. Munster,et al. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. , 2005, Cancer research.
[49] T. Okamoto,et al. Transcriptional Repression of Human Immunodeficiency Virus Type 1 by AP-4* , 2006, Journal of Biological Chemistry.
[50] A. Gartel. A new mode of transcriptional repression by c-myc: methylation , 2006, Oncogene.
[51] E. Verdin,et al. NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.
[52] Richard D Moore,et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. , 2007, The Journal of infectious diseases.